NCT02908477 - Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer | Biotech Hunter

Enrollment

228

Participants

Timeline

Start Date

October 3, 2016

Primary Completion Date

August 20, 2022

Study Completion Date

November 15, 2024

Conditions

Oropharynx Cancer

Interventions

RADIATION

Adjuvant Radiation Therapy

60 Gy / 2 Gy fractions (standard arm) 30 - 36 Gy / 1.5 - 1.8 Gy b.i.d. fractions (experimental arm)

DRUG

Docetaxel

15 mg/m2. Experimental arm only.

DRUG

Cisplatin

40 mg/m2. Standard arm only.

Trial Locations (2)

Mayo Clinic in Rochester, Rochester

Mayo Clinic in Arizona, Scottsdale